Butorphanol in Pain Following Ablation for Hepatic Tumor

NACompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

July 30, 2023

Study Completion Date

August 9, 2023

Conditions
Visceral PainMicrowave AblationHepatic Tumor
Interventions
DRUG

Butorphanol

The pharmacological attributes of Butorphanol, characterized by its mild impact on cardiopulmonary dynamics and demonstrated efficacy in attenuating mechanical traction-induced discomfort, culminate in an ameliorative effect on postoperative nausea and vomiting rates. Importantly, it substantively attenuates visceral postoperative pain. However, sedation can also cause dizziness, drowsiness, and other adverse reactions during recovery

DRUG

normal saline

normal saline contain 0.9% NaCl sodium.

Trial Locations (1)

200000

Jinling Hosipiatl, Nanjing

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Eastern Hepatobiliary Surgery Hospital

OTHER

lead

Bibo Wang

OTHER